Navigation Links
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
Date:4/9/2009

e period in the prior year. The increase in SG&A in the fourth quarter of 2008 was in line with the increased business activity in 2008. In particular, payroll and bonus, higher consulting fees, travel and other expenses drove the year-over-year increase.

Net expenditures on research and development expenses for the fourth quarter of 2008 were $359,000, compared to $354,000 in the same period of 2007. The R&D expenses in the quarter are mainly incurred for the advancement of its vaccine candidates in the pre-clinical development pipeline, including Sinovac's vaccine against EV 71 and its human rabies candidate.

Operating income was $3.1 million for the fourth quarter of 2008, compared to $3.3 million in the same period of 2007. The year-over-year variance in operating income reflected relatively moderate higher expense in the fourth quarter.

Net income for the fourth quarter of 2008 included $284,000 in income tax recovery, $327,000 interest and other income and $1.4 million of minority interest. Net income for the same period of 2007 included $184,000 of interest and financing expenses, $42,000 of income taxes expense, $111,000 other expenses and $965,000 of minority interest. Net income for the fourth quarter of 2008 was $2.4 million, or $0.06 per diluted share, compared to $2.0 million, or $0.05 per diluted share, in the same period of 2007.

As of December 31, 2008, Sinovac's cash and cash equivalents totaled $32.9 million, compared to $20.5 million as of September 30, 2008. The 60.4% increase in cash and cash equivalents compared to the third quarter of 2008 was primarily attributable to improved accounts receivables collection.

Recent Developments

Following the completion of a large scale, post-approval marketing study, the safety and immunogenicity of Sinovac's seasonal influenza vaccine, Anflu, was analyzed and reviewed by 18 provincial and
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
2. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
3. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
4. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
5. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
6. Sinovac Releases Statement on Healive Vaccine Suspension
7. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
8. Sinovac Named to Deloitte Technology Fast 50 China
9. Sinovac to Participate in Two Upcoming Investor Conferences
10. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
11. Sinovac Biotech Holds 2007 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... City, Ca. (PRWEB) August 28, 2014 ... E3 rating for an alcohol-based hand sanitizer, asks food ... harvest by comparing the hand sanitizer they’re currently using ... Spray . Hand hygiene is critical to fighting cross-contamination ... environment. Best Sanitizers believes there are key criteria ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... activity (regenerative potential) of stem cells and accelerates ... MaxCyte announces today the introduction of its ... Stem Cell Summit to be held in New ... is a validated, scalable technology for customizing the ...
... Feb. 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 clinical ... of Syncria (R) (albiglutide) in the long-term treatment ... HGS will receive a $9 million milestone payment in ...
... VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced ... (NDA) with the U.S. Food and Drug Administration (FDA) ... a single agent for remission induction treatment for patients ... novo poor-risk acute myeloid leukemia (AML). The ...
Cached Biology Technology:MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 2MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 2Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 3Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 4
(Date:8/29/2014)... The rise of the Tibetan plateau -- the largest ... important for both its profound effect on climate and ... in GSA Bulletin , Katharine Huntington and colleagues ... -- using modern and fossil snail shells to investigate ... Tibet. , Views range widely on the timing ...
(Date:8/28/2014)... This news release is available in German . ... fresh water fish, owes its name to a striking pattern ... cell types, black cells, reflective silvery cells, and yellow cells ... fish and arrange as a multilayered mosaic to compose the ... all three cell types have to interact to form proper ...
(Date:8/28/2014)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the Genetics Society of America,s 27th ... October 3, 2014 in Pacific Grove, California. ... entry of students, post doctorates and scientists from ... science community and to encourage the participation of ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... bumblebee species from an ecosystem and the impact is ... seeds, a new study finds. The study, to ... Academy of Sciences , focused on the interactions between ... results show how reduced competition among pollinators disrupts floral ...
... , July 26, 2013 /PRNewswire-iReach/ -- TestoMeds is ... discounts online for those seeking testosterone or progesterone ... deficiencies. (Photo: http://photos.prnewswire.com/prnh/20130726/MN54049 ) ... testosterone replacement creams – Androforte, Androfeme, and ...
... relevant information while ignoring distractions is a core brain ... "noise," we could not effectively interact with our environment. ... cellular mechanisms responsible for the effects of attention have ... in the journal Nature , researchers from Dartmouth,s ...
Cached Biology News:Bees 'betray' their flowers when pollinator species decline 2Bees 'betray' their flowers when pollinator species decline 3Bees 'betray' their flowers when pollinator species decline 4Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 2Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 3Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 4